PT-141

PT-141, sold under the brand name Vyleesi, is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). In 2019 the FDA approved bremelanotide as the first centrally-acting, non-hormonal treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women — a distinct mechanism from the hormonal therapies and PDE5 inhibitors that preceded it.

Unlike sildenafil or tadalafil, which act peripherally on vascular smooth muscle, PT-141 works in the brain. It targets melanocortin receptors in the hypothalamus and limbic system to modulate sexual motivation at the level of the central nervous system, making it the first approved pharmacological agent specifically for female sexual desire rather than arousal or lubrication.

Compounded bremelanotide is increasingly used off-label by both men and women through telehealth and peptide-prescribing clinics. Men’s off-label use — primarily for low libido or arousal difficulty — has no large randomized-trial evidence base; that application remains investigational and should be discussed with a provider experienced in sexual medicine.

PT-141 is a melanocortin receptor agonist with highest affinity for the melanocortin-4 receptor (MC4R) and secondary activity at MC1R [6]. MC4R is expressed throughout the hypothalamus, limbic system, and brainstem — regions that regulate sexual motivation, reward, and arousal. Activation of MC4R by bremelanotide is thought to increase dopaminergic and oxytocinergic signaling in the medial preoptic area, shifting the central balance toward pro-sexual drive.

This centrally-mediated pathway explains why PT-141 can affect desire and motivation rather than only genital blood flow. Animal studies using melanocortin agonists have consistently produced pro-sexual behaviors, and the clinical activity of bremelanotide in humans is mechanistically consistent with MC4R engagement [6]. A notable off-target effect is MC1R agonism, which activates melanocytes and can cause focal hyperpigmentation with repeated dosing.

The pivotal evidence for bremelanotide comes from two phase-3 randomized, double-blind, placebo-controlled trials (the RECONNECT program) enrolling premenopausal women with generalized acquired HSDD [1]. Both trials measured the co-primary endpoints of change in satisfying sexual events (SSEs) and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) distress score. Bremelanotide produced statistically significant improvements over placebo on both endpoints, establishing its efficacy as Grade A for the approved indication.

A 52-week open-label extension reported sustained benefit and a consistent adverse-event profile over long-term use, with no new safety signals emerging beyond those observed in the phase-3 period [2]. Prespecified subgroup analyses across age groups, contraception status, and baseline HSDD severity showed consistent directionality of effect, supporting generalizability of the response [4].

An expert pharmacotherapy evaluation published in 2023 contextualized bremelanotide within the limited landscape for female sexual dysfunction, noting that both bremelanotide and flibanserin offer modest-but-real effect sizes with distinct tolerability profiles, and that patient preference and nausea risk should guide selection [5].

Evidence for PT-141 in men is limited to mechanistic rationale and small, early-phase data without any published phase-3 RCT. Male off-label use relies on MC4R biology and clinical extrapolation; providers should disclose this limitation explicitly to patients before prescribing.

The FDA-approved regimen for Vyleesi (bremelanotide) is a single 1.75 mg subcutaneous injection administered approximately 45 minutes before anticipated sexual activity. No more than one dose should be used within 24 hours, and the labeling recommends a maximum of eight doses per month. The auto-injector is used in the abdomen or thigh.

Compounded bremelanotide — available through some telehealth and peptide clinics — typically uses the same 1.75 mg dose and is usually supplied as a lyophilized powder for reconstitution. Because compounded products are not FDA-reviewed for potency or sterility equivalence, patients should use only 503B-licensed compounding pharmacies and confirm their prescriber is monitoring appropriately.

The most common adverse effect across the RECONNECT trials and the long-term safety program was nausea, reported by approximately 40% of bremelanotide-treated participants versus fewer than 2% of placebo recipients [3]. Flushing and headache were also frequent. Nausea onset is typically within one hour of injection and resolves within a few hours; pre-dosing with an anti-emetic reduced severity in clinical practice.

A transient increase in blood pressure — averaging approximately 6 mmHg systolic and 3 mmHg diastolic — occurs within one hour of injection and resolves within 12 hours in most patients [3]. Bremelanotide is contraindicated in patients with known cardiovascular disease or uncontrolled hypertension. Focal hyperpigmentation of the face, gums, or breasts has been reported with repeated dosing due to MC1R activity and may be irreversible; patients must be counseled before initiating therapy.